Multicenter Italian Validation of EHP-30
Launched by UNIVERSITY OF CAGLIARI · Jan 25, 2015
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Previous surgical and histological diagnosis of endometriosis
- Exclusion Criteria:
- • Severe underlying comorbidities (gynecological, cardiovascular, respiratory, renal, hematological, endocrine, hepatic, gastrointestinal, neurological)
- • Psychiatric diseases
- • Refusal or inability to sign the informed consent
Trial Officials
Stefano Angioni, MD, PhD
Principal Investigator
University of Cagliari
About University Of Cagliari
The University of Cagliari is a prominent academic institution located in Sardinia, Italy, renowned for its commitment to advancing medical research and education. With a strong emphasis on innovative clinical trials, the university leverages its interdisciplinary expertise and state-of-the-art facilities to drive advancements in healthcare. The institution collaborates with a network of researchers, clinicians, and industry partners to facilitate cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Through its rigorous scientific approach and dedication to ethical research practices, the University of Cagliari plays a pivotal role in contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monserrato, Cagliari, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
